The difference in cancer detection
Cxbladder is a suite of non-invasive laboratory tests for the detection and the management of bladder cancer that provide actionable results to make a meaningful difference in a patient's treatment.
These clinically validated tests measure the change in gene expression levels of five biomarker genes that represent a signature for bladder cancer 1. Cxbladder Detect identifies patients showing changes in gene expression for bladder cancer2 whereas Cxbladder Triage combines the biomarker genes with known bladder cancer risk factors to help rule out cancer3 in patients with haematuria (blood in the urine) – quickly, easily and non-invasively.
- A suite of urine-based molecular tests to determine the likelihood of bladder cancer in patients presenting with haematuria
- Facilitates early detection of bladder cancer2 and helps rule out bladder cancer-free patients 3
- Effective adjunct to cystoscopy
- Can be used to replace other urine-based tests or replace the need for CT / IVP in some instances
- Easy to use - a complete sampling system is provided for collection and shipment of the patient's urine to our laboratory
Cxbladder is available in the following countries
- New Zealand – Through Pacific Edge Diagnostics NZ
- United States – Through Pacific Edge Diagnostics USA
- Australia – Through our commercial partner, Tolmar Australia
- Soon to be available in Spain – Through our licensed partner, Oryzon Genomics
For further information on Cxbladder, please visit: www.cxbladder.com
1 Holyoake et al: Development of a multiplex RNA urine test for the detection and stratification of transitional cell carcinoma of the bladder, Clin Cancer Res 2008; 14(3): 742-749
2 O'Sullivan et. al: A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria, J Urol 2012; 188: 741-747
3 Kavalieris et al: A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinoma, BMC Urology 2015; 15:23
Pacific Edge is responsible for the development and determination of the performance characteristics for Cxbladder. Because Cxbladder is a Laboratory Developed Test (LDT), Cxbladder has not been cleared or approved by the US Food and Drug Administration (FDA).